Ubs Group Ag Nymox Pharmaceutical Corp Transaction History

Ubs Group Ag

  • $452 Billion
  • Q3 2024

Shares

23 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 11, 2023
BUY
$0.19 - $0.49 $6,489 - $16,735
34,155 Added 9108.0%
34,530 $6,000
Q3 2022

Nov 10, 2022
SELL
$0.22 - $0.61 $121 - $335
-550 Reduced 59.46%
375 $0
Q2 2022

Aug 10, 2022
BUY
$0.38 - $1.41 $142 - $528
375 Added 68.18%
925 $0
Q4 2021

Feb 14, 2022
SELL
$0.95 - $2.1 $2,643 - $5,844
-2,783 Reduced 83.5%
550 $1,000
Q3 2021

Nov 15, 2021
SELL
$1.3 - $2.23 $2,455 - $4,212
-1,889 Reduced 36.17%
3,333 $7,000
Q2 2021

Aug 13, 2021
SELL
$1.46 - $2.48 $20,241 - $34,382
-13,864 Reduced 72.64%
5,222 $8,000
Q1 2021

May 12, 2021
BUY
$2.22 - $3.39 $16,825 - $25,692
7,579 Added 65.86%
19,086 $42,000
Q4 2020

Feb 11, 2021
BUY
$1.84 - $2.83 $18,212 - $28,011
9,898 Added 615.16%
11,507 $28,000
Q3 2020

Nov 12, 2020
SELL
$2.3 - $3.66 $27,875 - $44,359
-12,120 Reduced 88.28%
1,609 $4,000
Q2 2020

Jul 31, 2020
BUY
$2.1 - $4.6 $26,453 - $57,946
12,597 Added 1112.81%
13,729 $49,000
Q1 2020

May 01, 2020
SELL
$1.69 - $3.88 $1,725 - $3,961
-1,021 Reduced 47.42%
1,132 $3,000
Q4 2019

Feb 14, 2020
SELL
$1.73 - $2.42 $1,681 - $2,352
-972 Reduced 31.1%
2,153 $5,000
Q3 2019

Nov 14, 2019
SELL
$1.41 - $2.12 $2,741 - $4,121
-1,944 Reduced 38.35%
3,125 $6,000
Q2 2019

Aug 14, 2019
SELL
$1.33 - $2.12 $2,431 - $3,875
-1,828 Reduced 26.5%
5,069 $7,000
Q1 2019

May 14, 2019
SELL
$1.57 - $2.71 $7,928 - $13,685
-5,050 Reduced 42.27%
6,897 $14,000
Q4 2018

Feb 14, 2019
BUY
$1.31 - $2.53 $2,760 - $5,330
2,107 Added 21.41%
11,947 $16,000
Q3 2018

Nov 14, 2018
BUY
$2.46 - $3.7 $14,063 - $21,152
5,717 Added 138.66%
9,840 $24,000
Q2 2018

Aug 14, 2018
BUY
$3.12 - $4.33 $9,316 - $12,929
2,986 Added 262.62%
4,123 $14,000
Q1 2018

May 15, 2018
SELL
$3.09 - $4.43 $9,572 - $13,724
-3,098 Reduced 73.15%
1,137 $5,000
Q4 2017

Feb 14, 2018
SELL
$3.29 - $4.06 $2,921 - $3,605
-888 Reduced 17.33%
4,235 $14,000
Q3 2017

Nov 14, 2017
SELL
$3.36 - $4.02 $73,812 - $88,311
-21,968 Reduced 81.09%
5,123 $19,000
Q2 2017

Aug 14, 2017
BUY
N/A
12,573 Added 86.6%
27,091 $119,000
Q1 2017

Nov 14, 2017
BUY
N/A
14,518
14,518 $53,000

Others Institutions Holding NYMX

# of Institutions
6
Shares Held
150K
Call Options Held
0
Put Options Held
0
View Full List

About NYMOX PHARMACEUTICAL CORP

NYMX Quotes by TradingView
  • Ticker NYMX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 91,265,000
  • Market Cap $42.9M
  • Description
  • Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population in Canada, the United States, Europe, and internationally. Its lead drug candidate is Fexapotide Triflutate (NX-1207), which has completed Phase III clinical trials for the treatment of benign prostatic hyperpl...
More about NYMX
Track This Portfolio

Track Ubs Group Ag Portfolio

Follow Ubs Group Ag and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email